Tag: Carbapenem-based Antibiotics Market report

250 Pages Carbapenem-based Antibiotics Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider

According to Fact MR’s recent market research, sales of Carbapenem-based Antibiotics to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Focus on improving overall patient care will remain a chief growth driver. Besides this, Carbapenem-based Antibiotics market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

To remain ‘ahead’ of your competitors, request for a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=4425

The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Carbapenem-based Antibiotics market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Carbapenem-based Antibiotics

The report offers actionable and valuable market insights of Carbapenem-based Antibiotics. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Carbapenem-based Antibiotics Market across various industries and regions.

This newly published and insightful report sheds light on Market Insights of Carbapenem-based Antibiotics, key dynamics, their impact on the overall value chain from suppliers to end-users and Growth of Carbapenem-based Antibiotics Market.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4425

Key Segments of Carbapenem-based Antibiotics Market

Fact.MR’s study on the carbapenem-based antibiotics therapy market offers information divided into four important segments – product, indication, sales channel, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Product Type	Meropenem Ertapenem Imipenem Doripenem Panipenem Tebipenem
Indication	Intra-abdominal Infections Urinary Tract Infections Pneumonia Bacterial Meningitis Skin and Skin Structure Infections Acute Pelvic Infections Prophylaxis of Surgical Site Infection Respiratory Tract Infections Gynaecologic Infections Endocarditis Others
Sales Channel	Hospital Pharmacies Retail Pharmacies & Drug Stores Online Pharmacies
Region	North America Latin America Europe South Asia East Asia Oceania Middle East & Africa

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4425
 

Competitive Landscape

• Pfizer Inc.
• Merck Co. & Inc.
• Sumitomo Dainippon Pharma Co., Ltd.

are top players operating in the carbapenem-based antibiotics market. The top three players contributed more than 92% revenue share in the carbapenem-based antibiotics market in 2018.

Key players are prominently focusing on increasing their carbapenem-based antibiotics availability in different countries for the treatment of a large patient pool with bacterial infections.

Key Takeaways of Carbapenem-based Antibiotics Market Study

• Larger patient pools and launch of novel products for the treatment of bacterial infections are expected to shape the carbapenem-based antibiotics market landscape.
• Increasing prevalence of bacterial infections caused by longer stay in hospitals as well as immunocompromising chronic diseases that make patients prone to bacterial infections is expected to boost carbapenem-based antibiotics market growth.
• Currently, the carbapenem-based antibiotics market is dominated by ertapenem. However, tebipenem is expected to gain traction during the forecast period in terms of revenue.
• In terms of indication, pneumonia is expected to garner highest market share as compared to other bacterial infections owing to a large patient pool.

“ Recently, FDA granted Qualified Infectious Disease Product (QIDP) to sulopenem as well as tebipenem for new indications, which is further expected to broaden the growth prospect of the carbapenem-based antibiotics market,” says the Fact.MR Analyst.

Read More Trending Reports of Fact.MR- https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/

Report Benefits & Key Questions Answered

• Carbapenem-based Antibiotics Category and segment level analysis: Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.
• Carbapenem-based Antibiotics Historical volume analysis: The report provides a comparison of Carbapenem-based Antibiotics’s historical sales and projected sales performance for 2021-2031.
• Carbapenem-based Antibiotics Manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the Carbapenem-based Antibiotics market. It carefully gauges the impact of changing healthcare needs of key demographics globally
• Carbapenem-based Antibiotics Consumption by demographics: The report investigates consumer behavior affecting Carbapenem-based Antibiotics demand outlook for the assessment period. Effect of their keenness for digital trends on Carbapenem-based Antibiotics market is carefully analyzed
• Post COVID consumer spending on Carbapenem-based Antibiotics: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting Carbapenem-based Antibiotics market growth.

More Valuable Insights on Carbapenem-based Antibiotics Market

Fact.MR, in its new report, offers an unbiased Market Analysis of Carbapenem-based Antibiotics, Sales and Demand of Carbapenem-based Antibiotics, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Shower Chairs Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Infrared Thermometer Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Fact.MR has adopted multi-disciplinary approach to shed light on the evolution of the Carbapenem-based Antibiotics  Market during the historical period. The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year of 2019, and key prospects over the forecast period. The insights and analytics on the  Carbapenem-based Antibiotics  Market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity assessment, end-use/application prospects analysis, and competitive landscape assessment.

Sample Report   https://www.factmr.com/connectus/sample?flag=S&rep_id=4425

The following insights and evaluations are worth knowing for any market participant, helping them in ascertaining the prevailing dynamics and the future trajectories of the Carbapenem-based Antibiotics    Market. They are a part of the estimations of the opportunities in various segments. The additional new opportunities have turned the Carbapenem-based Antibiotics    Market into a fragmented landscape with more entry-level players entering the market, thanks to low barriers for investments. The research report published by Fact.MR on the Carbapenem-based Antibiotics   Market provides a detailed overview of the demands and consumptions of various products/services associated with the growth dynamics of the market during the forecast period.

The in-depth market estimation of various opportunities in the segments is expressed in volumes and revenues. The insights and analytics on the Carbapenem-based Antibiotics    market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity assessment, end-use/application prospects analysis, and competitive landscape assessment.

Buy Now  https://www.factmr.com/checkout/4425

After reading the Carbapenem-based Antibiotics    Market report, readers get insight into: 

• Major drivers and restraining factors, opportunities and challenges, and the competitive landscape
• New, promising avenues in key regions
• New revenue streams for all players in emerging markets
• Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions
• Demand and uptake patterns in key industries of the Carbapenem-based Antibiotics    Market
• New research and development projects in new technologies in key regional markets
• Changing revenue share and size of key product segments during the forecast period
• Technologies and business models with disruptive potential 

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM)
• EU – (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
• CIS & Russia
• Japan
• Asia Pacific Excluding Japan (Greater China, India, S. Korea, ASEAN Countries, Rest of APEJ)
• Middle East and Africa (GCC Countries, Turkey, Iran, Israel, South Africa, Rest of MEA)

The Report Covers Exhaustive Analysis On:

• Market Segments
• Market Dynamics
• Market Size & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

The Carbapenem-based Antibiotics    Market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period. In coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.

Some important questions that the Carbapenem-based Antibiotics    Market report tries to answer exhaustively are: 

• Key strategic moves by various players in the Carbapenem-based Antibiotics    Market in recent years with respect to product launches, deals and tie-ups, and mergers and acquisitions, and divestment of shares
• Which strategies will enable top players in the Carbapenem-based Antibiotics    Market to expand their geographic footprint
• Which new business models are expected to change the course of growth of key regional markets in near future
• Which technologies will witness most attractive research investments and what will be the key sources of funding for startups and new entrants
• Which products segments have in recent years have seen new, lucrative application areas

 Report Methodology https://www.factmr.com/connectus/sample?flag=RM&rep_id=4425

Benefits of Fact.MR Study

Fact.MR has gradually established itself as one of the leading market research companies across the globe. Our unique, methodical, and up-to-date approach towards creating high-quality market reports ensures the reports include relevant market insights. Further, our team of analysts leaves no stone unturned while curating market reports in accord with the requirement of our clients.  

Why Choose Fact.MR?

1. Deliver updated information on the current industry trends
2. Available 24/7 to facilitate clients with unbiased solutions
3. Embrace digital technologies to offer accurate business ideas
4. Exhaustive supply chain augmentation analysis
5. Provide reports strictly according to the requirements of the clients

For More Insights- https://www.newswire.co.kr/newsRead.php?no=923711

 About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.

 Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

250 Pages Carbapenem-based Antibiotics Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider

According to Fact MR’s recent market research, sales of Carbapenem-based Antibiotics to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Focus on improving overall patient care will remain a chief growth driver. Besides this, Carbapenem-based Antibiotics market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

To remain ‘ahead’ of your competitors, request for a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=4425

To offer an in-depth overview, the report provides sales projections for over 20 countries. It also identifies segments exhibiting maximum growth.

Digital Transformation in Healthcare Presenting Opportunities for Carbapenem-based Antibiotics Market Growth

Healthcare organizations around the world are deploying digital tools to accommodating changing consumer preferences. They are pressing on solving the long-standing challenge pertaining to care model innovation.

Considering this, the focus on making healthcare affordable and more transparent will increase. Adoption of care model innovation in healthcare will have a profound impact on the Carbapenem-based Antibiotics market.

The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Carbapenem-based Antibiotics market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Carbapenem-based Antibiotics

The report offers actionable and valuable market insights of Carbapenem-based Antibiotics. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Carbapenem-based Antibiotics Market across various industries and regions.

This newly published and insightful report sheds light on Market Insights of Carbapenem-based Antibiotics, key dynamics, their impact on the overall value chain from suppliers to end-users and Growth of Carbapenem-based Antibiotics Market.

Key Segments of Carbapenem-based Antibiotics Market

Fact.MR’s study on the carbapenem-based antibiotics therapy market offers information divided into four important segments – product, indication, sales channel, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4425

Product Type	Meropenem Ertapenem Imipenem Doripenem Panipenem Tebipenem
Indication	Intra-abdominal Infections Urinary Tract Infections Pneumonia Bacterial Meningitis Skin and Skin Structure Infections Acute Pelvic Infections Prophylaxis of Surgical Site Infection Respiratory Tract Infections Gynaecologic Infections Endocarditis Others
Sales Channel	Hospital Pharmacies Retail Pharmacies & Drug Stores Online Pharmacies
Region	North America Latin America Europe South Asia East Asia Oceania Middle East & Africa

Carbapenem-based Antibiotics Market – Scope of Report

Fact.MR recently published a market study on the global market for carbapenem-based antibiotics. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the carbapenem-based antibiotics market structure. The market study presents exclusive information about how the carbapenem-based antibiotics market will grow during the forecast period 2019-2029.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in Fact.MR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the carbapenem-based antibiotics market during the forecast period.

The study is relevant for stakeholders in the carbapenem-based antibiotics market, including carbapenem-based antibiotics products manufactures, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the carbapenem-based antibiotics market, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in Fact.MR’s study.

The study also includes statistics as well as facts related to macroeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the carbapenem-based antibiotics market. Furthermore, small businesses and new entrants in the carbapenem-based antibiotics market too can make use of the information presented in this study, based on, which they can make appropriate business decisions to gain momentum in the carbapenem-based antibiotics market.

Key Takeaways of Carbapenem-based Antibiotics Market Study

• Larger patient pools and launch of novel products for the treatment of bacterial infections are expected to shape the carbapenem-based antibiotics market landscape.
• Increasing prevalence of bacterial infections caused by longer stay in hospitals as well as immunocompromising chronic diseases that make patients prone to bacterial infections is expected to boost carbapenem-based antibiotics market growth.
• Currently, the carbapenem-based antibiotics market is dominated by ertapenem. However, tebipenem is expected to gain traction during the forecast period in terms of revenue.
• In terms of indication, pneumonia is expected to garner highest market share as compared to other bacterial infections owing to a large patient pool.

“ Recently, FDA granted Qualified Infectious Disease Product (QIDP) to sulopenem as well as tebipenem for new indications, which is further expected to broaden the growth prospect of the carbapenem-based antibiotics market,” says the Fact.MR Analyst.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4425


Report Benefits & Key Questions Answered

• Carbapenem-based Antibiotics Category and segment level analysis: Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.
• Carbapenem-based Antibiotics Historical volume analysis: The report provides a comparison of Carbapenem-based Antibiotics’s historical sales and projected sales performance for 2021-2031.
• Carbapenem-based Antibiotics Manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the Carbapenem-based Antibiotics market. It carefully gauges the impact of changing healthcare needs of key demographics globally
• Carbapenem-based Antibiotics Consumption by demographics: The report investigates consumer behavior affecting Carbapenem-based Antibiotics demand outlook for the assessment period. Effect of their keenness for digital trends on Carbapenem-based Antibiotics market is carefully analyzed
• Post COVID consumer spending on Carbapenem-based Antibiotics: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting Carbapenem-based Antibiotics market growth.

More Valuable Insights on Carbapenem-based Antibiotics Market

Fact.MR, in its new report, offers an unbiased Market Analysis of Carbapenem-based Antibiotics, Sales and Demand of Carbapenem-based Antibiotics, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Shower Chairs Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Infrared Thermometer Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Read More Trending Reports of Fact.MR-

https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

 

Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 – 2021. Incidence of bacterial infections is increasing rapidly across the world offering significant revenue generating opportunities for the carbapenem-based antibiotics market.

Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of patent for ertapenem is expected to offer new avenues for market growth in regulated as well as non-regulated carbapenem-based antibiotics market where its adoption & availability are comparatively limited. On the back of these factors, the global sales of carbapenem-based antibiotics is estimated to reach a valuation of US$1.8 Bn by 2029.

For detailed insights on enhancing your product footprint, request for a sample here- 

https://www.factmr.com/connectus/sample?flag=S&rep_id=4425

“ Recently, FDA granted Qualified Infectious Disease Product (QIDP) to sulopenem as well as tebipenem for new indications, which is further expected to broaden the growth prospect of the carbapenem-based antibiotics market,” says the Fact.MR Analyst.

Key Takeaways of Carbapenem-based Antibiotics Market Study

• Larger patient pools and launch of novel products for the treatment of bacterial infections are expected to shape the carbapenem-based antibiotics market landscape.
• Increasing prevalence of bacterial infections caused by longer stay in hospitals as well as immunocompromising chronic diseases that make patients prone to bacterial infections is expected to boost carbapenem-based antibiotics market growth.
• Currently, the carbapenem-based antibiotics market is dominated by ertapenem. However, tebipenem is expected to gain traction during the forecast period in terms of revenue.
• In terms of indication, pneumonia is expected to garner highest market share as compared to other bacterial infections owing to a large patient pool.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4425]

Fact.MR’s study on the carbapenem-based antibiotics therapy market offers information divided into four important segments – product, indication, sales channel, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Key Segments of Carbapenem-based Antibiotics Market

Product Type	Meropenem Ertapenem Imipenem Doripenem Panipenem Tebipenem
Indication	Intra-abdominal Infections Urinary Tract Infections Pneumonia Bacterial Meningitis Skin and Skin Structure Infections Acute Pelvic Infections Prophylaxis of Surgical Site Infection Respiratory Tract Infections Gynaecologic Infections Endocarditis Others
Sales Channel	Hospital Pharmacies Retail Pharmacies & Drug Stores Online Pharmacies
Region	North America Latin America Europe South Asia East Asia Oceania Middle East & Africa

Strategic Expansion by Dominant Players Benefiting Market

The carbapenem-based antibiotics market is dominated by top three players including Merck Co. & Inc., Pfizer Inc., and Sumitomo Dainippon Pharma Co., Ltd. These leading players in the carbapenem-based antibiotics market contribute around 80% to 90% revenue share. Clinical stage companies such as Spero Therapeutic Inc. and Iterum Therapeutics Inc. with the launch of their novel carbapenem-based antibiotics are expected to acquire significant market space. In October 2017, Spero Therapeutics, Inc. and Meiji Seika Pharma Co., Ltd. announced an exclusive licensed partnership for its carbapenem-based antibiotic named SPR994 (tebipenem). In a similar development, Sumitomo Dainippon Pharma in June 2017, announced a partnership with Zuellig Pharma for sales of carbapenem-based antibiotic meropenem in five countries of Southeast Asia (Vietnam, Thailand, Singapore, Philippines, Malaysia) and Hong Kong.

Full Access of this Exclusive Report is Available at-
https://www.factmr.com/checkout/4425

Key Questions Answered in Fact.MR’s Carbapenem-based Antibiotics Market Report

• Which regions will continue to remain the most profitable regional markets for carbapenem-based antibiotics market players?
• Which factors will essentially induce a change in the demand for carbapenem-based antibiotics in the forecast period?
• How will changing trends impact the carbapenem-based antibiotics market?
• What are key manufacturers’ strategy to enhance their product adoption and improve regional product footprints?
• Which companies are leading the carbapenem-based antibiotics market?

For More Insights
https://www.biospace.com/article/epidermal-cell-sheets-sales-surges-due-to-growing-need-for-effective-and-safe-guiding-technology-says-fact-mr/

Looking for more information?

The research study on carbapenem-based antibiotics market by Fact.MR incorporates an unbiased assessment of key demand-driving factors and trends which have shaped the landscape of carbapenem-based antibiotics over 2014 – 2018 and includes a detailed assessment of key parameters that are anticipated to exert influence over 2019 – 2029. Market statistics have been presented on the basis of product type (Meropenem, imipenem, ertapenem, tebipenem, doripenem, panipenem, etc.), indication (intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, prophylaxis of surgical site infection, respiratory tract infections, others), sales channel (hospital pharmacies, retail pharmacies, online pharmacies) across seven major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 – 2021. Incidence of bacterial infections is increasing rapidly across the world offering significant revenue generating opportunities for the carbapenem-based antibiotics market.

Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of patent for ertapenem is expected to offer new avenues for market growth in regulated as well as non-regulated carbapenem-based antibiotics market where its adoption & availability are comparatively limited. On the back of these factors, the global sales of carbapenem-based antibiotics is estimated to reach a valuation of US$1.8 Bn by 2029.

For detailed insights on enhancing your product footprint, request for a sample here- 

https://www.factmr.com/connectus/sample?flag=S&rep_id=4425

“ Recently, FDA granted Qualified Infectious Disease Product (QIDP) to sulopenem as well as tebipenem for new indications, which is further expected to broaden the growth prospect of the carbapenem-based antibiotics market,” says the Fact.MR Analyst.

Key Takeaways of Carbapenem-based Antibiotics Market Study

• Larger patient pools and launch of novel products for the treatment of bacterial infections are expected to shape the carbapenem-based antibiotics market landscape.
• Increasing prevalence of bacterial infections caused by longer stay in hospitals as well as immunocompromising chronic diseases that make patients prone to bacterial infections is expected to boost carbapenem-based antibiotics market growth.
• Currently, the carbapenem-based antibiotics market is dominated by ertapenem. However, tebipenem is expected to gain traction during the forecast period in terms of revenue.
• In terms of indication, pneumonia is expected to garner highest market share as compared to other bacterial infections owing to a large patient pool.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4425]

Fact.MR’s study on the carbapenem-based antibiotics therapy market offers information divided into four important segments – product, indication, sales channel, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Key Segments of Carbapenem-based Antibiotics Market

Product Type	Meropenem Ertapenem Imipenem Doripenem Panipenem Tebipenem
Indication	Intra-abdominal Infections Urinary Tract Infections Pneumonia Bacterial Meningitis Skin and Skin Structure Infections Acute Pelvic Infections Prophylaxis of Surgical Site Infection Respiratory Tract Infections Gynaecologic Infections Endocarditis Others
Sales Channel	Hospital Pharmacies Retail Pharmacies & Drug Stores Online Pharmacies
Region	North America Latin America Europe South Asia East Asia Oceania Middle East & Africa

Strategic Expansion by Dominant Players Benefiting Market

The carbapenem-based antibiotics market is dominated by top three players including Merck Co. & Inc., Pfizer Inc., and Sumitomo Dainippon Pharma Co., Ltd. These leading players in the carbapenem-based antibiotics market contribute around 80% to 90% revenue share. Clinical stage companies such as Spero Therapeutic Inc. and Iterum Therapeutics Inc. with the launch of their novel carbapenem-based antibiotics are expected to acquire significant market space. In October 2017, Spero Therapeutics, Inc. and Meiji Seika Pharma Co., Ltd. announced an exclusive licensed partnership for its carbapenem-based antibiotic named SPR994 (tebipenem). In a similar development, Sumitomo Dainippon Pharma in June 2017, announced a partnership with Zuellig Pharma for sales of carbapenem-based antibiotic meropenem in five countries of Southeast Asia (Vietnam, Thailand, Singapore, Philippines, Malaysia) and Hong Kong.

Full Access of this Exclusive Report is Available at-
https://www.factmr.com/checkout/4425

Key Questions Answered in Fact.MR’s Carbapenem-based Antibiotics Market Report

• Which regions will continue to remain the most profitable regional markets for carbapenem-based antibiotics market players?
• Which factors will essentially induce a change in the demand for carbapenem-based antibiotics in the forecast period?
• How will changing trends impact the carbapenem-based antibiotics market?
• What are key manufacturers’ strategy to enhance their product adoption and improve regional product footprints?
• Which companies are leading the carbapenem-based antibiotics market?

For More Insights
https://www.biospace.com/article/epidermal-cell-sheets-sales-surges-due-to-growing-need-for-effective-and-safe-guiding-technology-says-fact-mr/

Looking for more information?

The research study on carbapenem-based antibiotics market by Fact.MR incorporates an unbiased assessment of key demand-driving factors and trends which have shaped the landscape of carbapenem-based antibiotics over 2014 – 2018 and includes a detailed assessment of key parameters that are anticipated to exert influence over 2019 – 2029. Market statistics have been presented on the basis of product type (Meropenem, imipenem, ertapenem, tebipenem, doripenem, panipenem, etc.), indication (intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, prophylaxis of surgical site infection, respiratory tract infections, others), sales channel (hospital pharmacies, retail pharmacies, online pharmacies) across seven major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com